AxoGen, Inc. (NASDAQ:AXGN) tinted gains of +4.33% (+0.8 points) to US$19.26. The volume of 0.87 Million shares climbed down over an trading activity of 840.74 Million shares. EPS ratio determined by looking at last 12 month figures is -0.54. Over the same time span, the stock marked US$56.85 as its best level and the lowest price reached was US$14.13. The corporation has a market cap of US$746.9 Million.
AxoGen, Inc. (NASDAQ:AXGN)’s earnings per share has been growing at a 18.1 percent rate over the past 5 year when average revenue increase was noted as 51 percent. The return on equity ratio or ROE stands at -22.7 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 90.5 percent. The company’s net profit margin has achieved the current level of -25.4 percent and possesses 82.7 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.67. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Astec Industries, Inc. (NASDAQ:ASTE) is worth US$898.91 Million and has recently risen 4.32% to US$39.81. The latest exchange of 0.7 Million shares is below its average trading activity of 202.63 Million shares. The day began at US$40 but the price moved to US$39.3 at one point during the trading and finally capitulating to a session high of US$43.26. The stock tapped a 52-week high of US$63.69 while the mean 12-month price target for the shares is US$38.5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.41, and a price to sales ratio of 0.77. For the past 5 years, the company’s revenue has grown 4.8%, while the company’s earnings per share has grown 1.4%. With an institutional ownership near 92.3%, it carries an earnings per share ratio of -0.16.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.